Harvard Bio Unloads Part of Its Capital Equipment Biz for $1M, Plus Earn-out | GenomeWeb

Harvard Bio Unloads Part of Its Capital Equipment Biz for $1M, Plus Earn-out

Dec 04, 2007

NEW YORK (GenomeWeb News) - Harvard Bioscience said yesterday that it has sold its Genomics Solutions division and Maia Scientific business to Digilab for $1 million in cash and a 20 percent earn-out of the revenue the businesses generate over a three-year, post-transaction period.

Both businesses were part of the company’s Capital Equipment Business Segment, which Harvard Bio has been trying to sell for more than two years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Laureates Warn Against Hard Brexit

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

For All

Vox reports on inequities in genetic research and efforts to address them.

Lawrence Krauss to Retire Following Sexual Misconduct Allegations

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

This Week in PNAS

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.